Comparative Pharmacology
Head-to-head clinical analysis: RAU SED versus RAUSERPIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAU SED versus RAUSERPIN.
RAU-SED vs RAUSERPIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reserpine depletes catecholamines (norepinephrine, dopamine) from adrenergic nerve endings by binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing neurotransmitter storage and leading to depletion of catecholamines.
Rauwolfia alkaloid (reserpine) depletes catecholamines (norepinephrine, dopamine, serotonin) from sympathetic nerve endings and brain by irreversibly binding to vesicular monoamine transporter (VMAT). This results in reduced sympathetic outflow, decreased heart rate, and vasodilation.
Initial: 0.5 mg orally once daily; maintenance: 0.1-0.25 mg orally once daily.
Initial: 0.1-0.25 mg orally once daily; increase gradually to 0.5-1 mg per day in 2 divided doses. Maximum: 3 mg/day.
None Documented
None Documented
Terminal elimination half-life: 45-90 hours (average 60 hours); clinical context: requires 5-7 days to reach steady-state; prolonged half-life may lead to cumulative effects
Terminal elimination half-life: 4-8 hours; clinical context: requires multiple daily dosing to maintain therapeutic levels.
Renal (60-70% as unchanged drug and metabolites); fecal (20-30% via biliary elimination)
Primarily renal (60-70% as unchanged drug and metabolites); biliary/fecal (15-20%)
Category C
Category C
Antihypertensive
Antihypertensive